Your browser doesn't support javascript.
loading
A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα.
Jauslin, Werner Theodor; Schild, Matthias; Schaefer, Thorsten; Borsari, Chiara; Orbegozo, Clara; Bissegger, Lukas; Zhanybekova, Saule; Ritz, Danilo; Schmidt, Alexander; Wymann, Matthias; Gillingham, Dennis.
Afiliación
  • Jauslin WT; Department of Chemistry, University of Basel 4056 Basel Switzerland dennis.gillingham@unibas.ch.
  • Schild M; Department of Chemistry, University of Basel 4056 Basel Switzerland dennis.gillingham@unibas.ch.
  • Schaefer T; Department of Biomedicine, University of Basel 4031 Basel Switzerland matthias.wymann@unibas.ch.
  • Borsari C; Department of Biomedicine, University of Basel 4031 Basel Switzerland matthias.wymann@unibas.ch.
  • Orbegozo C; Department of Biomedicine, University of Basel 4031 Basel Switzerland matthias.wymann@unibas.ch.
  • Bissegger L; Department of Biomedicine, University of Basel 4031 Basel Switzerland matthias.wymann@unibas.ch.
  • Zhanybekova S; Department of Chemistry, University of Basel 4056 Basel Switzerland dennis.gillingham@unibas.ch.
  • Ritz D; Proteomics Core Facility, Biozentrum, University of Basel 4056 Basel Switzerland.
  • Schmidt A; Proteomics Core Facility, Biozentrum, University of Basel 4056 Basel Switzerland.
  • Wymann M; Department of Biomedicine, University of Basel 4031 Basel Switzerland matthias.wymann@unibas.ch.
  • Gillingham D; Department of Chemistry, University of Basel 4056 Basel Switzerland dennis.gillingham@unibas.ch.
Chem Sci ; 15(2): 683-691, 2024 Jan 03.
Article en En | MEDLINE | ID: mdl-38179525
ABSTRACT
Class I phosphoinositide 3-kinases (PI3Ks) control cellular growth, but are also essential in insulin signaling and glucose homeostasis. Pan-PI3K inhibitors thus generate substantial adverse effects, a reality that has plagued drug development against this target class. We present here evidence that a high affinity binding module with the capacity to target all class I PI3K isoforms can facilitate selective degradation of the most frequently mutated class I isoform, PI3Kα, when incorporated into a cereblon-targeted (CRBN) degrader. A systematic proteomics study guided the fine tuning of molecular features to optimize degrader selectivity and potency. Our work resulted in the creation of WJ112-14, a PI3Kα-specific nanomolar degrader that should serve as an important research tool for studying PI3K biology. Given the toxicities observed in the clinic with unselective PI3Kα inhibitors, the results here offer a new approach toward selectively targeting this frequently mutated oncogenic driver.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Chem Sci Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Chem Sci Año: 2024 Tipo del documento: Article